EN zh-TW

newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / / MarketScreener

Biogen to pay up to $850 million to acquire exclusive rights in Greater China to an experimental immune disease treatment.

Biogen will pay TJ Biopharma up to $850 million for Greater China rights to felzartamab.

KEY POINTS
COMPANIES
Read the full story on MarketScreener → →
Share X LinkedIn

Summarized by Newsio from MarketScreener. How we summarize →

RELATED 03
genai · news · 3h 211

MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today launched ReefIQ™.

  • MindWalk launched ReefIQ, a HYFT-powered biological context layer for AI-driven drug discovery workflows.
  • ReefIQ links fragmented client discovery data into MindWalk's governed, queryable biological context foundation.
Business Wire →
biotech · news · 4h 202

Cancer cells can stay hidden in the body for years before causing a relapse.

  • Breast cancer cells mimic healthy stem cells to survive undetected in bone marrow niches.
  • Notch2, but not Notch1, plays a significant role in inducing dormancy within breast cancer cells.
Drug Target Review →
biotech · news · 13h 203

Meningioma is the most common brain tumor in adults.

  • Mayo Clinic's study mapped over 500,000 individual meningioma tumor cells using single-cell sequencing.
  • Distinct immune cell states in the tumor microenvironment predict aggressiveness and recurrence risk.
News-Medical →